Evolution of H3N2 influenza virus in a Guinea pig model

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Long, Jinxue ^a,d   Bushnell, Ruth V ^a   Tobin, John K ^a   Pan, Keyao ^b   Deem, Michael W ^b   Nara, Peter L ^a,c   Tobin, Gregory J ^a,c  

^a Biological Mimetics Inc   (United States)

^b RICE UNIVERSITY   (United States)

^c IOWA STATE UNIVERSITY   (United States)

^d Shanghai Veterinary Research Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEMAGGLUTININ; VIRUS RNA; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENIC VARIATION; ARTICLE; CONTROLLED STUDY; DOMINANT GENE; EPITOPE MAPPING; EVOLUTIONARY ADAPTATION; EXPERIMENTAL GUINEA PIG; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMAGGLUTININ GENE; HYDROPHOBICITY; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; MOLECULAR EVOLUTION; MOLECULAR RECOGNITION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROGENY; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; VIRUS IMMUNITY; VIRUS MUTANT; VIRUS MUTATION; ANIMAL; CELL LINE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DOG; GENETICS; GLYCOSYLATION; GUINEA PIG; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; PROTEIN CONFORMATION; VIROLOGY;

ANIMALIA; CAVIA; ORTHOMYXOVIRIDAE;

ANIMALS; CELL LINE; DOGS; EPITOPES; EVOLUTION, MOLECULAR; GLYCOSYLATION; GUINEA PIGS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNIZATION; INFLUENZA A VIRUS, H3N2 SUBTYPE; MODELS, ANIMAL; MODELS, MOLECULAR; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN CONFORMATION; VIRAL VACCINES;

EID: 79960690084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020130     Document Type: Article

References (42)

1. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, et al. (2008) The genomic and epidemiological dynamics of human influenza A virus. Nature 453: 615-619.
2. WHO Influenza (2003) WHO Influenza fact sheet. Wkly Epidemiol Rec 78: 77-80.
3. Centers for Disease Control and Prevention (2008) Update: influenza activity-United States, September 30, 2007-February 9, 2008. MMWR Morb Mortal Wkly Rep 57: 179-183.
4. Grebe KM, Yewdell JW, Bennink JR, (2008) Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10: 1024-1029.
5. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25: 5086-5096.
6. Gupta V, Earl DJ, Deem MW, (2006) Quantifying influenza vaccine efficacy and antigenic distance. Vaccine 24: 3881-3888.
7. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, et al. (2008) Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26: 6189-6199.
8. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P, (2006) The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A 103: 9988-9992.
9. Batschelet E, Domingo E, Weissmann C, (1976) The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene 1: 27-32.
10. Caporale LH, (2003) Natural selection and the emergence of a mutation phenotype: an update of the evolutionary synthesis considering mechanisms that affect genome variation. Annu Rev Microbiol 57: 467-485.
11. Manrubia SC, Lázaro E, (2006) Viral evolution. Physics of Life Reviews 3: 65-92.
12. Bouvier NM, Lowen AC, Palese P, (2008) Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 82: 10052-10058.
13. Herlocher ML, Elias S, Truscon R, Harrison S, Mindell D, et al. (2001) Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis 184: 542-546.
14. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.
15. Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, et al. (2007) Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J Virol 81: 6890-6898.
16. Bushnell RV, Tobin JK, Long J, Schultz-Cherry S, Chaudhuri AR, et al. (2010) Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein. Virol J 7: 200.
17. Lambkin R, McLain L, Jones SE, Aldridge SL, Dimmock NJ, (1994) Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J Gen Virol 75 (Pt 12): 3493-3502.
18. Pan K, Long J, Sun H, Tobin GJ, Nara PL, et al. (2011) Selective Pressure to Increase Charge in Immunodominant Epitopes of the H3 Hemagglutinin Influenza Protein. J Mol Evol 72: 90-103.
19. Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T, (1998) Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol 5: 119-123.
20. Munoz ET, Deem MW, (2005) Epitope analysis for influenza vaccine design. Vaccine 23: 1144-1148.
21. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437: 1162-1166.
22. Holmes EC, (2003) Error thresholds and the constraints to RNA virus evolution. Trends Microbiol 11: 543-546.
23. Kaverin NV, Rudneva IA, Govorkova EA, Timofeeva TA, Shilov AA, et al. (2007) Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 81: 12911-12917.
24. Keleta L, Ibricevic A, Bovin NV, Brody SL, Brown EG, (2008) Experimental evolution of human influenza virus H3 hemagglutinin in the mouse lung identifies adaptive regions in HA1 and HA2. J Virol 82: 11599-11608.
25. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
26. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3: e2517.
27. Pan K, Subieta KC, Deem MW, (2011) A Novel Sequence-Based Antigenic Distance Measure for H1N1, with Application to Vaccine Effectiveness and the Selection of Vaccine Strains. Protein Eng Des Sel 24: 291-299.
28. Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT, (1997) The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study. J Biol Chem 272: 4027-4036.
29. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, et al. (2007) N-linked glycosylation attenuates H3N2 influenza viruses. J Virol 81: 8593-8600.
30. Mishin VP, Novikov D, Hayden FG, Gubareva LV, (2005) Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J Virol 79: 12416-12424.
31. Alymova IV, Taylor G, Mishin VP, Watanabe M, Murti KG, et al. (2008) Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. J Virol 82: 8400-8410.
32. Inkster MD, Hinshaw VS, Schulze IT, (1993) The hemagglutinins of duck and human H1 influenza viruses differ in sequence conservation and in glycosylation. J Virol 67: 7436-7443.
33. Earl DJ, Deem MW, (2004) Evolvability is a selectable trait. Proc Natl Acad Sci U S A 101: 11531-11536.
34. Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, et al. (2010) How Can Vaccines Against Influenza and Other Viral Diseases Be Made More Effective? Plos Biol 8: e1000571.
35. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, et al. (2010) Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201: 1644-1653.
36. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 5: e13162.
37. Nara PL, (1999) Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Adv Vet Med 41: 115-134.
38. Nara PL, Garrity R, (1998) Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 16: 1780-1787.
39. Kilbourne ED, (1969) Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 41: 643-645.
40. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
41. Palmer DF, Coleman MT, Dowdle WR, Schild GC, (1975) Haemagglutination inhibition test: Laboratory Techniques for Influenza Diagnosis. Laboratory Techniques for Influenza Diagnosis Atlanta, Georgia US Department of Health, Education and Welfare.
42. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-51.